MENU

SNDX Stock Tickeron detected bearish Stock Pattern: Head-and-Shoulders Top SNDX on September 06, 2024, netting in a 30.59% gain over 3 months

A.I.dvisor
at Tickeron.com
Loading...
+30.59% Gain from a Successful pattern Head-and-Shoulders Top
SNDX - Syndax Pharmaceuticals
Tickeron
Ticker: SNDX
Company: Syndax Pharmaceuticals
Gain from shortening: +30.59%
Confirmed: 09/06/24
Succeeded: 12/11/24
Total length: 114 days
On August 19, 2024, A.I.dvisor detected a Head-and-Shoulders Top Pattern (Bearish) for Syndax Pharmaceuticals (SNDX, $20.50). 18 days later, on September 06, 2024, A.I.dvisor confirmed the Bearish pattern, setting a target price of the stock. On December 11, 2024, the stock hit the target price of $13.77 – resulting in a +3 gain for traders who shorted the stock on the pattern detection date.

SNDX sees MACD Histogram just turned negative

SNDX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 10, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 09, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 10-day moving average for SNDX crossed bearishly below the 50-day moving average on November 18, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNDX entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.047) is normal, around the industry mean (14.529). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). SNDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (67.114) is also within normal values, averaging (255.281).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for novel cancer therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
35 Gatehouse Drive
Phone
+1 781 419-1400
Employees
184
Web
https://www.syndax.com